Novo Nordisk completes $4.7 billion acquisition of Akero Therapeutics
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Wall Street ends higher as tech rebounds before Nvidia results
- Oil settles down more than 3%; investors shrug off US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Wall Street ends higher as tech rebounds before Nvidia results
- Intuit (INTU) Tops Q4 EPS; Offers FY27 Guidance
- Oppenheimer Upgrades Capricor Therapeutics (CAPR) to Outperform 'on Approval Optimism'
- Dick's Sporting Goods (DKS) Misses Q2 EPS by 25c, Offers Guidance
Novo Nordisk has completed its acquisition of Akero Therapeutics
December 9, 2025 8:52 AM ESTBagsværd, Denmark and South San Francisco, CA, US, 9 December 2025 Novo Nordisk and Akero Therapeutics Inc. (Akero) (Nasdaq: AKRO) today announced that Novo Nordisks acquisition of Akero, announced on 9 October 2025, has been completed.
With the completion of the transaction, Novo Nordisk has acquired all outstanding shares of common stock and common stock equivalents of Akero for 54 USD per share in cash (or aggregated value of 4.7 billion USD) and a non-transferable Contingent Value Right (CVR). Each CVR entitles its holder to an additional payment of 6 USD per share in cash (or aggregated value of 0.5... More
